Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 17/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 16/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7369320 | 0.84 | PDE4A (0.48) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL18909742 | 0.81 | PDE7A (0.37) | PDE4APDE4BPDE4DPDE4CHTR2A | |
| SCHEMBL18683207 | 0.78 | HTR2A (0.36) | PDE4APDE4BPDE4DPDE4CHTR2A | |
| SCHEMBL7374352 | 0.71 | PDE4A (0.49) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL7376901 | 0.70 | PDE4A (0.65) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL7395757 | 0.69 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL6637350 | 0.69 | PDE4A (0.47) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL14455896 | 0.69 | PDE4A (0.84) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL7376871 | 0.68 | PDE4A (0.60) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL14028559 | 0.68 | PDE4A (0.45) | PDE4APDE4BPDE4DPDE4CADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1380585-A1 | Pyrazolopyridinone | Pfizer Products Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1048667-B1 | Process for preparing 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3A,7,8-pentaaza-as-indacenes and intermediates useful therein | PFIZER PROD INC (US) | 2003-10-22 | — | — | EP | disclosed |
| EP-0837860-B1 | TRICYCLIC 5,6-DIHYDRO-9H-PYRAZOLO(3,4-c]-1,2,4-TRIAZOLO(4,3-ALPHA]PYRIDINES | PFIZER (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6326495-B2 | HEATING A MIXTURE OF CAPROLACTONE AND P-METHOXYBENZYLAMINE; CYCLIZATION | PFIZER INC. | 2001-12-04 | — | — | US | disclosed |
| US-20010039347-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein | PFIZER PRODUCTS INC. | 2001-11-08 | — | — | US | disclosed |
| EP-1048667-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3A,7,8-pentaaza-as-indacenes and intermediates useful therein | Pfizer Products Inc. (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6004974-A | PHOSPHODIESTERASE AND TUMOR NECROSIS FACTOR INHIBITORS; ANTIINFLAMMATORY AND ANTIASTHMA AGENTS | PFIZER INC (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0837860-A1 | TRICYCLIC 5,6-DIHYDRO-9H-PYRAZOLO 3,4-c]-1,2,4-TRIAZOLO 4,3-$g(a)]PYRIDINES | PFIZER INC. (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0787132-A1 | BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES AND THEIR USE AS MEDICAMENTS | PFIZER INC. (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996039408-A1 | TRICYCLIC 5,6-DIHYDRO-9H-PYRAZOLO[3,4-c]-1,2,4-TRIAZOLO[4,3-α]PYRIDINES | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996012720-A1 | BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES AND THEIR USE AS MEDICAMENTS | PFIZER INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| EP-0707585-A1 | BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES | PFIZER INC. (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001980-A1 | BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES | PFIZER INC. (US) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039347-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein | ADH1A, ADH1C, OTC | PDE4A 1915/4885PDE4B 2742/4885PDE4D 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.